Showing results (351-360 of 698) with videos related to
Sort By:
Pageof 70
Nature Reviews. Disease Primers|May 19, 2016
Diabetic kidney diseaseMerlin C Thomas, Michael Brownlee, Katalin Susztak, et al.Diabetes Research and Clinical Practice|March 5, 2025
Association between interleukin-6, suPAR, and hsCRP with subclinical left ventricular dysfunction in type 1 diabetes: The Thousand & 1 studyHashmat Sayed Zohori Bahrami, Peter Godsk Jørgensen, Jens Dahlgaard Hove, et al.Kidney International|October 6, 2022
Diabetes management in chronic kidney disease: a consensus report by the American Diabetes Association (ADA) and Kidney Disease: Improving Global Outcomes (KDIGO)Ian H de Boer, Kamlesh Khunti, Tami Sadusky, et al.Cardiovascular Diabetology|October 17, 2020
MR-proANP and incident cardiovascular disease in patients with type 2 diabetes with and without heart failure with preserved ejection fractionJesper Jensen, Morten Schou, Caroline Kistorp, et al.Kidney & Blood Pressure Research|April 4, 2023
International Variability of Renal and Cardiovascular Outcomes and Mortality in Patients with Type 2 Diabetes Mellitus in EuropeStefanie Thöni, Felix Keller, Sara Denicolò, et al.Journal of Internal Medicine|July 7, 2025
Soluble urokinase plasminogen activator receptor and interleukin-6 improves prediction of all-cause mortality and major adverse cardiovascular events in Type 1 diabetesHashmat Sayed Zohori Bahrami, Peter Godsk Jørgensen, Jens Dahlgaard Hove, et al.Diabetologia|May 23, 2026
A randomised clinical trial testing the safety of and metabolic responses to short-term duodenal infusion of recombinant RORDEP1 in healthy menJoachim Gæde, Yong Fan, Liwei Lyu, et al.Diabetes, Obesity & Metabolism|July 11, 2018
N-terminal pro-brain natriuretic peptide (NT-proBNP) predicts the cardio-renal response to aliskiren in patients with type 2 diabetes at high renal and cardiovascular riskNienke M A Idzerda, Frederik Persson, Michelle J Pena, et al.Plos One|June 13, 2023
Diabetes treatment for persons with severe mental illness: A registry-based cohort study to explore medication treatment differences for persons with type 2 diabetes with and without severe mental illnessCatrine Bakkedal, Frederik Persson, Margit Kriegbaum, et al.JAMA Network Open|October 26, 2022
Association of Finerenone Use With Reduction in Treatment-Emergent Pneumonia and COVID-19 Adverse Events Among Patients With Type 2 Diabetes and Chronic Kidney Disease: A FIDELITY Pooled Secondary AnalysisBertram Pitt, Rajiv Agarwal, Stefan D Anker, et al.Pageof 70